CAS 66778-36-7

Encainide

Description:

Encainide is a pharmaceutical compound primarily used as an antiarrhythmic agent. It belongs to the class of sodium channel blockers, which function by inhibiting the influx of sodium ions during the depolarization phase of cardiac action potentials. This action helps to stabilize the cardiac membrane and restore normal rhythm in patients experiencing arrhythmias. Encainide is characterized by its chemical structure, which includes a piperidine ring and an aromatic moiety, contributing to its pharmacological properties. The substance is typically administered in a controlled manner due to its potential side effects, which can include proarrhythmia, particularly in patients with pre-existing heart conditions. Encainide's efficacy and safety profile have been evaluated in clinical settings, and it is important for healthcare providers to monitor patients closely for any adverse reactions. As with many antiarrhythmic drugs, the therapeutic use of encainide requires careful consideration of the patient's overall health status and potential drug interactions.

Formula: C₂₂H₂₈N₂O₂

InChI: InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)

InChI key: InChIKey=PJWPNDMDCLXCOM-UHFFFAOYSA-N

SMILES: C(CC1N(C)CCCC1)C2=C(NC(=O)C3=CC=C(OC)C=C3)C=CC=C2

Synonyms:

• 4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide
• Benzamide,4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-, (?à)-
• Encainide
• Mj 9067
• Benzamide, 4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-, (±)-
• Benzamide, 4-methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-
• Encainide [french]
• MJ-9067[AS BASE]
• Enkaid
• M-9067-1
• Enkade
• 4-Methoxy-2'-[2-(1-methyl-3-piperidyl)ethyl]benzanilide
• Encainida
• Brn 0497572
• Encainidum

Encainide

CAS: 66778-36-7

Encainide is a class I antiarrhythmic drug that belongs to the group of class Ia drugs and inhibits the fast sodium channel. It slows the heart rate and decreases conduction velocity in cardiac tissue. Encainide has been shown to be effective against tachycardia and ventricular arrhythmias. It has been shown to have a stable dose-response curve as well as no known drug interactions. Encainide has also been shown to improve cardiac function by inhibiting the activity of beta-receptors in cardiac muscle, which may lead to increased contractility, improved relaxation, and increased blood flow. Encainide is mainly used for the treatment of arrhythmias in patients with certain heart conditions, such as papillary muscle dysfunction or cardiomyopathy.

Formula: C₂₂H₂₈N₂O₂

Purity: Min. 95%

Molecular weight: 352.5 g/mol

Ref: 3D-RCA77836